<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>PPROM: Clinical Management Update</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            background: #1a1a1a;
            color: #ffffff;
            overflow-x: hidden;
        }

        .slide-container {
            width: 100vw;
            height: 100vh;
            scroll-snap-type: y mandatory;
            overflow-y: scroll;
        }

        .slide {
            width: 100vw;
            height: 100vh;
            scroll-snap-align: start;
            display: flex;
            flex-direction: column;
            justify-content: center;
            align-items: center;
            padding: 60px;
            position: relative;
        }

        .slide-number {
            position: absolute;
            top: 30px;
            right: 40px;
            font-size: 14px;
            color: #666;
            font-weight: 300;
        }

        h1 {
            font-size: 72px;
            font-weight: 700;
            margin-bottom: 20px;
            text-align: center;
            line-height: 1.2;
        }

        h2 {
            font-size: 48px;
            font-weight: 600;
            margin-bottom: 40px;
            text-align: center;
            color: #4A90E2;
        }

        h3 {
            font-size: 36px;
            font-weight: 600;
            margin-bottom: 30px;
            color: #E8B339;
        }

        .subtitle {
            font-size: 28px;
            color: #999;
            margin-bottom: 60px;
            font-weight: 300;
        }

        .content-box {
            background: rgba(255, 255, 255, 0.05);
            border-left: 6px solid #4A90E2;
            padding: 40px;
            border-radius: 8px;
            max-width: 1200px;
            width: 100%;
        }

        .warning-box {
            background: rgba(231, 76, 60, 0.1);
            border-left: 6px solid #E74C3C;
            padding: 30px;
            border-radius: 8px;
            max-width: 1200px;
            width: 100%;
            margin-top: 20px;
        }

        .evidence-box {
            background: rgba(46, 204, 113, 0.1);
            border-left: 6px solid #2ECC71;
            padding: 30px;
            border-radius: 8px;
            max-width: 1200px;
            width: 100%;
            margin-top: 20px;
        }

        .consensus-box {
            background: rgba(241, 196, 15, 0.1);
            border-left: 6px solid #F1C40F;
            padding: 30px;
            border-radius: 8px;
            max-width: 1200px;
            width: 100%;
            margin-top: 20px;
        }

        .stat {
            font-size: 96px;
            font-weight: 700;
            color: #4A90E2;
            margin: 20px 0;
            text-align: center;
        }

        .stat-label {
            font-size: 28px;
            color: #ccc;
            text-align: center;
            margin-bottom: 40px;
        }

        ul {
            list-style: none;
            font-size: 28px;
            line-height: 1.8;
            max-width: 1200px;
        }

        li {
            margin: 20px 0;
            padding-left: 40px;
            position: relative;
        }

        li:before {
            content: "▸";
            position: absolute;
            left: 0;
            color: #4A90E2;
            font-weight: 700;
        }

        .two-column {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 40px;
            max-width: 1400px;
            width: 100%;
        }

        .column {
            background: rgba(255, 255, 255, 0.05);
            padding: 40px;
            border-radius: 8px;
        }

        .column h3 {
            font-size: 32px;
            margin-bottom: 25px;
            border-bottom: 3px solid #4A90E2;
            padding-bottom: 15px;
        }

        .column ul {
            font-size: 24px;
        }

        .highlight {
            color: #E8B339;
            font-weight: 600;
        }

        .timeline {
            display: flex;
            justify-content: space-between;
            max-width: 1400px;
            width: 100%;
            margin: 40px 0;
        }

        .timeline-item {
            text-align: center;
            flex: 1;
            padding: 20px;
            background: rgba(255, 255, 255, 0.05);
            margin: 0 10px;
            border-radius: 8px;
            border-top: 4px solid #4A90E2;
        }

        .timeline-ga {
            font-size: 32px;
            font-weight: 700;
            color: #4A90E2;
            margin-bottom: 15px;
        }

        .timeline-text {
            font-size: 20px;
            line-height: 1.4;
        }

        .protocol-box {
            background: rgba(74, 144, 226, 0.1);
            border: 2px solid #4A90E2;
            padding: 30px;
            border-radius: 8px;
            max-width: 1200px;
            width: 100%;
            margin: 20px 0;
        }

        .protocol-box h3 {
            color: #4A90E2;
            margin-bottom: 20px;
        }

        .dose {
            font-family: 'Courier New', monospace;
            background: rgba(0, 0, 0, 0.3);
            padding: 15px;
            border-radius: 4px;
            font-size: 22px;
            margin: 10px 0;
        }

        .key-point {
            font-size: 32px;
            font-weight: 600;
            color: #E8B339;
            text-align: center;
            padding: 30px;
            background: rgba(232, 179, 57, 0.1);
            border-radius: 8px;
            max-width: 1200px;
            margin: 20px 0;
        }

        table {
            width: 100%;
            max-width: 1200px;
            border-collapse: collapse;
            margin: 30px 0;
            font-size: 22px;
        }

        th {
            background: #4A90E2;
            padding: 20px;
            text-align: left;
            font-weight: 600;
        }

        td {
            padding: 20px;
            border-bottom: 1px solid rgba(255, 255, 255, 0.1);
        }

        tr:nth-child(even) {
            background: rgba(255, 255, 255, 0.02);
        }

        .evidence-level {
            display: inline-block;
            padding: 8px 16px;
            border-radius: 20px;
            font-size: 18px;
            font-weight: 600;
            margin-left: 15px;
        }

        .level-a {
            background: #2ECC71;
            color: #000;
        }

        .level-b {
            background: #F1C40F;
            color: #000;
        }

        .level-c {
            background: #95A5A6;
            color: #000;
        }

        .grid-3 {
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 30px;
            max-width: 1400px;
            width: 100%;
            margin: 30px 0;
        }

        .metric-card {
            background: rgba(255, 255, 255, 0.05);
            padding: 30px;
            border-radius: 8px;
            text-align: center;
            border-top: 4px solid #E74C3C;
        }

        .metric-value {
            font-size: 56px;
            font-weight: 700;
            color: #E74C3C;
            margin: 15px 0;
        }

        .metric-label {
            font-size: 20px;
            color: #ccc;
        }

        small {
            font-size: 18px;
            color: #888;
            font-style: italic;
        }
    </style>
</head>
<body>
    <div class="slide-container">
        
        <!-- Slide 1: Title -->
        <div class="slide">
            <h1>Preterm Premature Rupture<br>of Membranes</h1>
            <div class="subtitle">Evidence-Based Management</div>
            <div style="margin-top: 60px; font-size: 24px; color: #666;">
                ACOG/SMFM Clinical Update<br>
                Maternal-Fetal Medicine
            </div>
        </div>

        <!-- Slide 2: Objectives -->
        <div class="slide">
            <div class="slide-number">2</div>
            <h2>Learning Objectives</h2>
            <div class="content-box">
                <ul>
                    <li>Recognize PPROM epidemiology and pathophysiology</li>
                    <li>Apply evidence-based diagnostic criteria</li>
                    <li>Implement GA-specific management protocols</li>
                    <li>Counsel on maternal and fetal risks</li>
                    <li>Navigate areas of clinical uncertainty</li>
                </ul>
            </div>
        </div>

        <!-- Slide 3: Epidemiology -->
        <div class="slide">
            <div class="slide-number">3</div>
            <h2>Epidemiology</h2>
            <div class="stat">3%</div>
            <div class="stat-label">of all pregnancies</div>
            <div class="stat" style="font-size: 72px; margin-top: 40px;">30-40%</div>
            <div class="stat-label">of preterm births</div>
        </div>

        <!-- Slide 4: Pathophysiology -->
        <div class="slide">
            <div class="slide-number">4</div>
            <h2>Pathophysiology</h2>
            <div class="two-column">
                <div class="column">
                    <h3>Membrane Failure</h3>
                    <ul>
                        <li>Matrix metalloproteinases</li>
                        <li>Collagen degradation</li>
                        <li>Inflammatory mediators</li>
                        <li>Mechanical stress</li>
                    </ul>
                </div>
                <div class="column">
                    <h3>Infection Link</h3>
                    <ul>
                        <li>Bidirectional relationship</li>
                        <li>Cause or consequence</li>
                        <li>Ascending pathway risk</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Slide 5: Risk Factors - Strong Evidence -->
        <div class="slide">
            <div class="slide-number">5</div>
            <h2>Risk Factors</h2>
            <h3>Strong Evidence</h3>
            <div class="content-box">
                <ul>
                    <li>Prior PPROM (recurrence 16-32%)</li>
                    <li>Vaginal bleeding in pregnancy</li>
                    <li>Cigarette smoking</li>
                    <li>Short cervical length (<25mm)</li>
                    <li>Intraamniotic infection</li>
                </ul>
            </div>
        </div>

        <!-- Slide 6: Clinical Diagnosis -->
        <div class="slide">
            <div class="slide-number">6</div>
            <h2>Diagnosis: Clinical Triad</h2>
            <div class="evidence-box">
                <h3>Sterile Speculum Exam <span class="evidence-level level-a">Level A</span></h3>
                <ul style="font-size: 26px;">
                    <li><strong>Pooling:</strong> Amniotic fluid in posterior fornix</li>
                    <li><strong>Nitrazine:</strong> pH >6.5 (caution: false positives)</li>
                    <li><strong>Ferning:</strong> Microscopic crystallization pattern</li>
                </ul>
            </div>
            <div class="warning-box" style="margin-top: 30px;">
                <strong>Avoid digital cervical exam</strong> unless labor/delivery imminent
            </div>
        </div>

        <!-- Slide 7: Ancillary Tests -->
        <div class="slide">
            <div class="slide-number">7</div>
            <h2>When Diagnosis Unclear</h2>
            <div class="content-box">
                <h3>Commercial Tests</h3>
                <ul style="font-size: 24px;">
                    <li><strong>AmniSure (PAMG-1):</strong> Sens 98-99%, Spec 87-100%</li>
                    <li><strong>ROM Plus (IGFBP-1/AFP):</strong> Moderate accuracy</li>
                    <li><strong>Ultrasound:</strong> Oligohydramnios supports but not diagnostic</li>
                </ul>
            </div>
        </div>

        <!-- Slide 8: Management Overview -->
        <div class="slide">
            <div class="slide-number">8</div>
            <h2>Management by Gestational Age</h2>
            <div class="timeline">
                <div class="timeline-item">
                    <div class="timeline-ga">16-22⁶</div>
                    <div class="timeline-text">Periviable<br>Counseling-centered</div>
                </div>
                <div class="timeline-item">
                    <div class="timeline-ga">23-31⁶</div>
                    <div class="timeline-text">Expectant<br>ABX + Steroids</div>
                </div>
                <div class="timeline-item">
                    <div class="timeline-ga">32-33⁶</div>
                    <div class="timeline-text">Transition<br>Consider delivery</div>
                </div>
                <div class="timeline-item">
                    <div class="timeline-ga">34⁰-36⁶</div>
                    <div class="timeline-text">Delivery<br>at 34 weeks</div>
                </div>
            </div>
        </div>

        <!-- Slide 9: Periviable PPROM -->
        <div class="slide">
            <div class="slide-number">9</div>
            <h2>Periviable PPROM (16-22⁶ weeks)</h2>
            <div class="consensus-box">
                <h3>Counseling-Centered Approach <span class="evidence-level level-c">Consensus</span></h3>
                <ul style="font-size: 24px;">
                    <li>GA-specific survival and morbidity data</li>
                    <li>Pulmonary hypoplasia risk (10-26%)</li>
                    <li>Maternal risks (infection, retained placenta)</li>
                    <li>Offer expectant vs. delivery options</li>
                </ul>
            </div>
            <div class="warning-box" style="margin-top: 25px; font-size: 24px;">
                <strong>No corticosteroids</strong> at this gestational age
            </div>
        </div>

        <!-- Slide 10: Antibiotics -->
        <div class="slide">
            <div class="slide-number">10</div>
            <h2>Latency Antibiotics</h2>
            <div class="protocol-box">
                <h3>NICHD MFMU Protocol <span class="evidence-level level-a">Level A</span></h3>
                <div class="dose">
                    IV ampicillin 2g Q6h + IV erythromycin 250mg Q6h × 48h
                </div>
                <div class="dose">
                    ↓
                </div>
                <div class="dose">
                    PO amoxicillin 250mg Q8h + PO erythromycin 333mg Q8h × 5d
                </div>
            </div>
            <div class="warning-box" style="margin-top: 25px;">
                <strong>Avoid amoxicillin-clavulanate</strong> — associated with NEC
            </div>
        </div>

        <!-- Slide 11: Corticosteroids -->
        <div class="slide">
            <div class="slide-number">11</div>
            <h2>Antenatal Corticosteroids</h2>
            <div class="evidence-box">
                <h3>Strong Evidence for Benefit <span class="evidence-level level-a">Level A</span></h3>
                <div class="protocol-box" style="background: rgba(255,255,255,0.05); border-color: #2ECC71;">
                    <div class="dose">Betamethasone 12mg IM Q24h × 2 doses</div>
                    <div style="text-align: center; margin: 15px 0; font-size: 24px;">OR</div>
                    <div class="dose">Dexamethasone 6mg IM Q12h × 4 doses</div>
                </div>
                <ul style="font-size: 24px; margin-top: 25px;">
                    <li><strong>Indication:</strong> 23-34 weeks (some use through 36⁶)</li>
                    <li><strong>Reduces:</strong> RDS, IVH, NEC, neonatal mortality</li>
                </ul>
            </div>
        </div>

        <!-- Slide 12: Magnesium Sulfate -->
        <div class="slide">
            <div class="slide-number">12</div>
            <h2>Neuroprotection</h2>
            <div class="evidence-box">
                <h3>Magnesium Sulfate <span class="evidence-level level-a">Level A</span></h3>
                <div class="protocol-box" style="background: rgba(255,255,255,0.05); border-color: #2ECC71;">
                    <div class="dose">4-6g loading dose, then 1-2g/hr maintenance</div>
                </div>
                <ul style="font-size: 26px; margin-top: 25px;">
                    <li><strong>Indication:</strong> Delivery anticipated <32 weeks</li>
                    <li><strong>Benefit:</strong> Reduces cerebral palsy risk and severity</li>
                </ul>
            </div>
        </div>

        <!-- Slide 13: Delivery at 34 Weeks -->
        <div class="slide">
            <div class="slide-number">13</div>
            <h2>Late Preterm PPROM (34-36⁶ weeks)</h2>
            <div class="key-point">
                Delivery recommended at 34⁰ weeks
            </div>
            <div class="evidence-box">
                <h3>PPROMT Trial Evidence <span class="evidence-level level-a">Level A</span></h3>
                <ul style="font-size: 26px;">
                    <li>Reduces chorioamnionitis</li>
                    <li>Reduces neonatal infection</li>
                    <li>No increase in neonatal morbidity</li>
                </ul>
            </div>
        </div>

        <!-- Slide 14: Delivery Indications -->
        <div class="slide">
            <div class="slide-number">14</div>
            <h2>Indications for Delivery</h2>
            <div class="content-box">
                <ul style="font-size: 28px;">
                    <li><span class="highlight">Chorioamnionitis</span> (fever, tenderness, fetal tachycardia)</li>
                    <li><span class="highlight">Non-reassuring fetal status</span></li>
                    <li><span class="highlight">Placental abruption</span> (bleeding, pain)</li>
                    <li><span class="highlight">Advanced labor</span></li>
                    <li><span class="highlight">≥34 weeks gestation</span></li>
                </ul>
            </div>
        </div>

        <!-- Slide 15: Maternal Risks -->
        <div class="slide">
            <div class="slide-number">15</div>
            <h2>Maternal Risks</h2>
            <div class="grid-3">
                <div class="metric-card">
                    <div class="metric-label">Chorioamnionitis</div>
                    <div class="metric-value">13-60%</div>
                    <small>↑ with early GA, ↑ latency</small>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Abruption</div>
                    <div class="metric-value">4-12%</div>
                    <small>Higher than baseline</small>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Cord Prolapse</div>
                    <div class="metric-value">1-2%</div>
                    <small>↑ with oligohydramnios</small>
                </div>
            </div>
            <div class="content-box" style="margin-top: 30px;">
                <ul style="font-size: 22px;">
                    <li>Endometritis, sepsis (rare but serious)</li>
                    <li>Increased cesarean delivery risk</li>
                    <li>Recurrence risk in subsequent pregnancies</li>
                </ul>
            </div>
        </div>

        <!-- Slide 16: Fetal/Neonatal Risks -->
        <div class="slide">
            <div class="slide-number">16</div>
            <h2>Fetal/Neonatal Risks</h2>
            <div class="two-column">
                <div class="column">
                    <h3>Immediate</h3>
                    <ul style="font-size: 22px;">
                        <li>Neonatal sepsis/pneumonia</li>
                        <li>Cord compression/prolapse</li>
                        <li>Malpresentation</li>
                        <li>Placental abruption</li>
                    </ul>
                </div>
                <div class="column">
                    <h3>Prematurity-Related</h3>
                    <ul style="font-size: 22px;">
                        <li>RDS, BPD</li>
                        <li>IVH, PVL</li>
                        <li>NEC</li>
                        <li>ROP</li>
                        <li>Long-term neurodevelopmental</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Slide 17: Pulmonary Hypoplasia -->
        <div class="slide">
            <div class="slide-number">17</div>
            <h2>Pulmonary Hypoplasia</h2>
            <div class="warning-box">
                <h3 style="color: #E74C3C;">Periviable PPROM-Specific Risk</h3>
                <ul style="font-size: 26px;">
                    <li><strong>Incidence:</strong> 10-26% with PPROM <24 weeks</li>
                    <li><strong>Risk factors:</strong> Rupture <20 weeks, severe prolonged oligohydramnios</li>
                    <li><strong>Outcome:</strong> Often lethal or severe respiratory compromise</li>
                </ul>
            </div>
        </div>

        <!-- Slide 18: Counseling - Initial -->
        <div class="slide">
            <div class="slide-number">18</div>
            <h2>Initial Counseling</h2>
            <div class="content-box">
                <ul style="font-size: 24px;">
                    <li><strong>What happened:</strong> "Protective bag of water" has broken early</li>
                    <li><strong>Timing:</strong> Most deliver within 1 week; some longer latency</li>
                    <li><strong>Management:</strong> Hospitalization, antibiotics, steroids, monitoring</li>
                    <li><strong>Risks:</strong> Infection, preterm birth complications</li>
                    <li><strong>Signs to report:</strong> Fever, pain, foul discharge, bleeding, contractions</li>
                </ul>
            </div>
        </div>

        <!-- Slide 19: Counseling - GA-Specific -->
        <div class="slide">
            <div class="slide-number">19</div>
            <h2>GA-Specific Counseling</h2>
            <table>
                <thead>
                    <tr>
                        <th>Gestational Age</th>
                        <th>Key Counseling Points</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Periviable</strong></td>
                        <td>Full outcomes discussion; option for expectant vs. delivery; shared decision-making</td>
                    </tr>
                    <tr>
                        <td><strong>23-32 weeks</strong></td>
                        <td>Each week improves outcomes; goal to reach 34 weeks; NICU course likely</td>
                    </tr>
                    <tr>
                        <td><strong>34-36 weeks</strong></td>
                        <td>Excellent survival; delivery recommended at 34 weeks; may have mild respiratory issues</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <!-- Slide 20: Controversies - Timing -->
        <div class="slide">
            <div class="slide-number">20</div>
            <h2>Areas of Controversy</h2>
            <h3>Timing of Delivery (32-34 weeks)</h3>
            <div class="consensus-box">
                <ul style="font-size: 24px;">
                    <li><strong>Established:</strong> Delivery at 34 weeks superior to expectant management</li>
                    <li><strong>Uncertain:</strong> Optimal timing between 32-34 weeks</li>
                    <li><strong>Current practice:</strong> Varies by institution</li>
                </ul>
            </div>
        </div>

        <!-- Slide 21: Controversies - Outpatient -->
        <div class="slide">
            <div class="slide-number">21</div>
            <h2>Areas of Controversy</h2>
            <h3>Outpatient Management</h3>
            <div class="consensus-box">
                <ul style="font-size: 24px;">
                    <li><strong>Traditional:</strong> Hospitalization until delivery</li>
                    <li><strong>Evolving:</strong> Selected outpatient candidates after stabilization</li>
                    <li><strong>Uncertain:</strong> Patient selection criteria, GA limits, safety protocols</li>
                    <li><strong>Current:</strong> Most favor inpatient, especially <32 weeks</li>
                </ul>
            </div>
        </div>

        <!-- Slide 22: Controversies - Steroids Late Preterm -->
        <div class="slide">
            <div class="slide-number">22</div>
            <h2>Areas of Controversy</h2>
            <h3>Corticosteroids 34-36 Weeks</h3>
            <div class="consensus-box">
                <ul style="font-size: 24px;">
                    <li><strong>ALPS trial:</strong> Betamethasone reduces respiratory morbidity 34-36⁶ weeks</li>
                    <li><strong>ACOG guidance:</strong> Recommends for women at risk of delivery within 7 days</li>
                    <li><strong>Question:</strong> Does this apply to PPROM when delivery recommended at 34 weeks?</li>
                </ul>
            </div>
        </div>

        <!-- Slide 23: Controversies - Amniocentesis -->
        <div class="slide">
            <div class="slide-number">23</div>
            <h2>Areas of Controversy</h2>
            <h3>Amniocentesis for Infection Assessment</h3>
            <div class="consensus-box">
                <ul style="font-size: 24px;">
                    <li><strong>Potential:</strong> Could identify subclinical intraamniotic infection</li>
                    <li><strong>Challenges:</strong> Technical difficulty with oligohydramnios; unclear impact on management</li>
                    <li><strong>Current practice:</strong> Not routinely performed; rely on clinical signs</li>
                </ul>
            </div>
        </div>

        <!-- Slide 24: Evidence Summary -->
        <div class="slide">
            <div class="slide-number">24</div>
            <h2>Evidence Summary</h2>
            <div class="evidence-box">
                <h3><span class="evidence-level level-a">Level A</span> Strong Evidence (RCT/Meta-analysis)</h3>
                <ul style="font-size: 22px;">
                    <li>Latency antibiotics prolong pregnancy, reduce morbidity</li>
                    <li>Corticosteroids reduce RDS, IVH, NEC</li>
                    <li>Magnesium sulfate reduces cerebral palsy <32 weeks</li>
                    <li>Delivery at 34 weeks superior to expectant management</li>
                </ul>
            </div>
            <div class="consensus-box" style="margin-top: 25px;">
                <h3><span class="evidence-level level-c">Level C</span> Consensus-Based</h3>
                <ul style="font-size: 22px;">
                    <li>Inpatient vs. outpatient management</li>
                    <li>Antenatal testing protocols</li>
                    <li>Periviable PPROM counseling and management</li>
                </ul>
            </div>
        </div>

        <!-- Slide 25: Key Takeaways -->
        <div class="slide">
            <div class="slide-number">25</div>
            <h2>Clinical Pearls</h2>
            <div class="content-box">
                <ul style="font-size: 26px;">
                    <li>PPROM accounts for 30-40% of preterm births</li>
                    <li>Diagnosis primarily clinical; avoid digital exams</li>
                    <li>Antibiotics and steroids are evidence-based interventions</li>
                    <li>Deliver at 34 weeks; expectant management before</li>
                    <li>Infection risk increases with latency but balanced against prematurity</li>
                    <li>Counseling must be GA-specific and individualized</li>
                </ul>
            </div>
        </div>

        <!-- Slide 26: Summary -->
        <div class="slide">
            <div class="slide-number">26</div>
            <h2>Summary</h2>
            <div class="key-point" style="font-size: 28px; margin-bottom: 30px;">
                PPROM management balances risks of prematurity against risks of infection and oligohydramnios
            </div>
            <div class="content-box">
                <ul style="font-size: 24px;">
                    <li>Evidence-based interventions: antibiotics, corticosteroids, magnesium sulfate</li>
                    <li>GA-specific protocols optimize outcomes</li>
                    <li>Shared decision-making essential for periviable cases</li>
                    <li>Ongoing research addresses areas of uncertainty</li>
                </ul>
            </div>
        </div>

        <!-- Slide 27: References -->
        <div class="slide">
            <div class="slide-number">27</div>
            <h2>References</h2>
            <div class="content-box" style="font-size: 20px; line-height: 1.6;">
                <p style="margin-bottom: 15px;"><strong>ACOG Practice Bulletin No. 217:</strong> Prelabor Rupture of Membranes. Obstet Gynecol. 2020.</p>
                <p style="margin-bottom: 15px;"><strong>ACOG Committee Opinion No. 713:</strong> Antenatal Corticosteroid Therapy for Fetal Maturation. Obstet Gynecol. 2017.</p>
                <p style="margin-bottom: 15px;"><strong>ACOG Committee Opinion No. 455:</strong> Magnesium Sulfate Before Anticipated Preterm Birth for Neuroprotection. Obstet Gynecol. 2010 (Reaffirmed 2020).</p>
                <p style="margin-bottom: 15px;"><strong>Morris JM et al.</strong> Immediate delivery vs expectant management after preterm prelabour rupture of the membranes close to term (PPROMT trial). Lancet. 2016.</p>
                <p><strong>Mercer BM et al.</strong> Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. JAMA. 1997.</p>
            </div>
        </div>

    </div>

    <script>
        // Keyboard navigation
        document.addEventListener('keydown', function(e) {
            const slides = document.querySelectorAll('.slide');
            const currentSlide = Math.round(window.scrollY / window.innerHeight);
            
            if (e.key === 'ArrowDown' || e.key === 'ArrowRight' || e.key === ' ') {
                if (currentSlide < slides.length - 1) {
                    slides[currentSlide + 1].scrollIntoView({ behavior: 'smooth' });
                }
                e.preventDefault();
            } else if (e.key === 'ArrowUp' || e.key === 'ArrowLeft') {
                if (currentSlide > 0) {
                    slides[currentSlide - 1].scrollIntoView({ behavior: 'smooth' });
                }
                e.preventDefault();
            } else if (e.key === 'Home') {
                slides[0].scrollIntoView({ behavior: 'smooth' });
                e.preventDefault();
            } else if (e.key === 'End') {
                slides[slides.length - 1].scrollIntoView({ behavior: 'smooth' });
                e.preventDefault();
            }
        });

        // Click navigation hint
        document.querySelectorAll('.slide').forEach((slide, index, slides) => {
            slide.addEventListener('click', function(e) {
                if (e.clientX > window.innerWidth / 2 && index < slides.length - 1) {
                    slides[index + 1].scrollIntoView({ behavior: 'smooth' });
                } else if (e.clientX <= window.innerWidth / 2 && index > 0) {
                    slides[index - 1].scrollIntoView({ behavior: 'smooth' });
                }
            });
        });
    </script>
</body>
</html>